FDA Approves First Targeted Therapy for CSU in More Than a Decade

Jason Hawkes, MD, MS, a Dermatologist and Investigator at Oregon Medical Research Center in Portland, OR, discusses the significance and implications of the U.S. Food and Drug Administration’s approval of dupilumab (Dupixent, Sanofi & Regeneron) for patients aged 12+ years with uncontrolled Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite use of H1-antihistamines. “It’s a win in dermatology […]